Cargando…

Discontinuation of the renin–angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes

Renin–angiotensin system (RAS) blockade by angiotensin-converting enzyme inhibitors (ACEis) or angiotensin-receptor blockers (ARBs) has been related to anemia in various situations. We aimed to investigate whether discontinuation of RAS inhibitors improves erythropoiesis in patients with lower-risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pavlidis, George, Papageorgiou, Sotirios G., Bazani, Efthimia, Bouchla, Anthi, Glezou, Eirini, Gkontopoulos, Konstantinos, Thomopoulos, Thomas, Pappa, Vasiliki, Vlahakos, Demetrios V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809530/ https://www.ncbi.nlm.nih.gov/pubmed/33489062 http://dx.doi.org/10.1177/2040620720958299

Ejemplares similares

Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis—A Case Report
por: Bouchla, Anthi, et al.
Publicado: (2018)

Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience
por: Bouchla, Anthi, et al.
Publicado: (2019)

Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1
por: Mpakou, Vassiliki, et al.
Publicado: (2021)

MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis
por: Papageorgiou, Sotirios G., et al.
Publicado: (2017)

PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Sotirios, Papageorgiou, et al.
Publicado: (2023)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

Interplay of Vitamin D, Erythropoiesis, and the Renin-Angiotensin System
por: Santoro, Domenico, et al.
Publicado: (2015)

Erdheim–Chester Disease and Acute Myeloid Leukemia with Mutated NPM1 in a Patient with Clonal Hematopoiesis: A Case Report
por: Papageorgiou, Sotirios G, et al.
Publicado: (2020)

PB1917: PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF ELEMENTS OF THE ADAPTIVE IMMUNITY IN THE MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACITIDINE
por: Tsakiraki, Z., et al.
Publicado: (2022)

Multiple osteolytic lesions due to Double-Expressor Primary non-Hodgkin Lymphoma of the Bone
por: Papageorgiou, Sotirios, et al.
Publicado: (2020)

Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome?
por: Bouchla, Anthi, et al.
Publicado: (2023)

Red Blood Cell Abnormalities as the Mirror of SARS-CoV-2 Disease Severity: A Pilot Study
por: Bouchla, Anthi, et al.
Publicado: (2022)

PB1765: DIFFERENTIAL GENE EXPRESSION PROFILE IN DNA DAMAGE SIGNALING PATHWAYS, IN DE NOVO ACUTE MYELOID LEUKEMIA AND LOW-RISK MDS PATIENTS
por: Bouchla, Anthi, et al.
Publicado: (2023)

Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase
por: Fokoloros, Christos, et al.
Publicado: (2022)

Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?
por: Bobkova, Irina, et al.
Publicado: (2020)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management
por: Thomopoulos, Thomas P., et al.
Publicado: (2022)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

Primary Adrenal Lymphomas with Cushing’s Syndrome: Two Cases with Evidence of Endogeneous Cortisol Production by the Neoplastic Lymphoid Cells
por: Papageorgiou, Sotirios G., et al.
Publicado: (2023)

Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction
por: Darden, Douglas, et al.
Publicado: (2019)

Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes
por: An, Jaejin, et al.
Publicado: (2023)

Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate
por: Mpakou, Vassiliki, et al.
Publicado: (2017)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

What’s new in the renin-angiotensin system?: What’s new in the renin-angiotensin system?
por: Smith, A. I., et al.
Publicado: (2004)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

Effect of Discontinuation of Renin Angiotensin-System Inhibitors in Patients With Advanced Chronic Kidney Disease: A Meta-Analysis
por: Naveed, Husnain, et al.
Publicado: (2023)

Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis
por: Suzuki, Taihei, et al.
Publicado: (2023)

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
por: Horváth-Puhó, Erzsébet, et al.
Publicado: (2018)

The Renin-Angiotensin System Textbook
por: Cumming, Allan D
Publicado: (1994)

Brain renin angiotensin in disease
por: Phillips, M. Ian, et al.
Publicado: (2008)

Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis
por: Tang, Chen, et al.
Publicado: (2023)

Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions
por: Feidakis, Athanasios, et al.
Publicado: (2021)

Pure Red Cell Aplasia due to B19 Parvovirus Infection after Autologous Stem Cell Transplantation
por: Tsirigotis, Panagiotis, et al.
Publicado: (2011)

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes
por: Elvarsdóttir, Edda María, et al.
Publicado: (2019)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial
por: Rathkolb, Vincent, et al.
Publicado: (2023)

Do Genetic Variants of the Renin-Angiotensin System Predict Blood Pressure Response to Renin-Angiotensin System–Blocking Drugs? A Systematic Review of Pharmacogenomics in the Renin-Angiotensin System
por: Konoshita, Tadashi
Publicado: (2011)

The renin–angiotensin system and diabetes: An update
por: Ribeiro-Oliveira, Antônio, et al.
Publicado: (2008)

ANGIOTENSIN AND RENIN IN RAT AND DOG BRAIN
por: Fischer-Ferraro, Catalina, et al.
Publicado: (1971)

The renin-angiotensin system and aging in the kidney
por: Yoon, Hye Eun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_db7nsov8a8cu9j5sclfgsm7rom